An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)

Lung Cancer

Volumn 104, Issue , 2017, Pages 126-130

  Awad, Mark M ^a   Chu, Quincy S C ^b   Gandhi, Leena ^a   Stephenson, Joe J ^c   Govindan, Ramaswamy ^d   Bradford, Daniel S ^e   Bonomi, Philip D ^f   Ellison, David M ^g   Eaton, Keith D ^h   Fritsch, Holger ⁱ   Munzert, Gerd ⁱ   Johnson, Bruce E ^a   Socinski, Mark A ^j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Cancer Centers of the Carolinas   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Highlands Oncology Group   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g Charleston Hematology Oncology Associates   (United States)

^h SEATTLE CANCER CARE ALLIANCE   (United States)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

BI 2536; Plk 1 inhibition; Polo like kinase; Small cell lung cancer

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; SINGLE DRUG DOSE; SMALL CELL LUNG CANCER; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; INTRAVENOUS DRUG ADMINISTRATION; LUNG NEOPLASMS; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; SMALL CELL LUNG CARCINOMA; SMOKING; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; CELL CYCLE PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RECURRENCE; SMALL CELL LUNG CARCINOMA; SMOKING; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85009517335     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.12.019     Document Type: Article

References (38)

1. [1] American Cancer Society, Small Cell Lung Cancer Survival Rates by Stage. 2015.
2. [2] O'Brien, M.E., Ciuleanu, T.E., Tsekov, H., et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J. Clin. Oncol. 24 (2006), 5441–5447.
3. [3] von Pawel, J., Jotte, R., Spigel, D.R., et al. Randomized phase III trial of amrubicin versus topotecan As second-Line treatment for patients with small-Cell lung cancer. J. Clin. Oncol. 32 (2014), 4012–4019.
4. [4] Strebhardt, K., Ullrich, A., Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 6 (2006), 321–330.
5. [5] Barr, F.A., Sillje, H.H., Nigg, E.A., Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 5 (2004), 429–440.
6. [6] Jackson, J.R., Patrick, D.R., Dar, M.M., et al. Targeted anti-mitotic therapies: can we improve on tubulin agents?. Nat. Rev. Cancer 7 (2007), 107–117.
7. [7] Golsteyn, R.M., Schultz, S.J., Bartek, J., et al. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci. 107:Pt 6 (1994), 1509–1517.
8. [8] de Carcer, G., Manning, G., Malumbres, M., From Plk1 to Plk5: functional evolution of polo-like kinases. ABBV Cell Cycle 10 (2011), 2255–2262.
9. [9] Chan, E.H., Santamaria, A., Sillje, H.H., et al. Plk1 regulates mitotic Aurora A function through betaTrCP-dependent degradation of hBora. Chromosoma 117 (2008), 457–469.
10. [10] Shao, H., Huang, Y., Zhang, L., et al. Spatiotemporal dynamics of Aurora B-PLK1-MCAK signaling axis orchestrates kinetochore bi-orientation and faithful chromosome segregation. Sci. Rep., 5, 2015, 12204.
11. [11] Takai, N., Hamanaka, R., Yoshimatsu, J., et al. Polo-like kinases (Plks) and cancer. Oncogene 24 (2005), 287–291.
12. [12] Yamamoto, Y., Matsuyama, H., Kawauchi, S., et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 70 (2006), 231–237.
13. [13] Tokumitsu, Y., Mori, M., Tanaka, S., et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int. J. Oncol. 15 (1999), 687–692.
14. [14] Liu, X., Erikson, R.L., Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 5789–5794.
15. [15] Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J. Natl. Cancer Inst. 94 (2002), 1863–1877.
16. [16] Driscoll, D.L., Chakravarty, A., Bowman, D., et al. Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines. PLoS One, 9, 2014, e111060.
17. [17] Steegmaier, M., Hoffmann, M., Baum, A., et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr. Biol. 17 (2007), 316–322.
18. [18] Wildey, G., Chen, Y., Lent, I., et al. Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer. PLoS One, 9, 2014, e106784.
19. [19] Hofheinz, R.D., Al-Batran, S.E., Hochhaus, A., et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin. Cancer Res. 16 (2010), 4666–4674.
20. [20] Mross, K., Frost, A., Steinbild, S., et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 26 (2008), 5511–5517.
21. [21] Sebastian, M., Reck, M., Waller, C.F., et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J. Thor. Oncol. 5 (2010), 1060–1067.
22. [22] von Pawel, J., Ardizzoni, A., Thatcher, N., et al. P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studies. Lung Cancer, 41, 2016, S235.
23. [23] von Pawel, J., Schiller, J.H., Shepherd, F.A., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J. Clin. Oncol. 17 (1999), 658–667.
24. [24] Johnson, B.E., Fischer, T., Fischer, B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. 9 (2003), 5880–5887.
25. [25] Asai, N., Ohkuni, Y., Kaneko, N., et al. Relapsed small cell lung cancer: treatment options and latest developments. Ther. Adv. Med. Oncol. 6 (2014), 69–82.
26. [26] Gehan, E.A., The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 13 (1961), 346–353.
27. [27] Eckardt, J.R., von Pawel, J., Pujol, J.L., et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25 (2007), 2086–2092.
28. [28] Schoffski, P., Blay, J.Y., De Greve, J., et al. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur. J. Cancer 46 (2010), 2206–2215.
29. [29] Mross, K., Dittrich, C., Aulitzky, W.E., et al. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas − a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br. J. Cancer 107 (2012), 280–286.
30. [30] Frost, A., Mross, K., Steinbild, S., et al. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr. Oncol. 19 (2012), e28–35.
31. [31] Ellis, P.M., Chu, Q.S., Leighl, N., et al. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin. Lung Cancer 14 (2013), 19–27.
32. [32] Lee, K.-H., Schlenk, R.F., Bug, G., et al. Polo-like kinase-1 (Plk-1) inhibitor BI 2536 induces mitotic arrest and apoptosis in vivo: first demonstration of target inhibition in the bone marrow of AML patients. Blood, 112, 2008, 2641.
33. [33] Haupenthal, J., Bihrer, V., Korkusuz, H., et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia 14 (2012), 410–419.
34. [34] Gjertsen, B.T., Schoffski, P., Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 29 (2015), 11–19.
35. [35] Rudolph, D., Steegmaier, M., Hoffmann, M., et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin. Cancer Res. 15 (2009), 3094–3102.
36. [36] Lin, C.C., Su, W.C., Yen, C.J., et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br. J. Cancer 110 (2014), 2434–2440.
37. [37] Stadler, W.M., Vaughn, D.J., Sonpavde, G., et al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 120 (2014), 976–982.
38. [38] Yim, H., Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 24 (2013), 999–1006.